---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-065928"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2024-03-12T23:59:59+00:00"
generated_at: "2026-06-04T22:46:20.743932+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lexicon files certificate for Series A Convertible Preferred Stock; conversion requires charter amendment

## Summary
- Each Preferred share converts into 50 common shares upon stockholder approval to increase authorized shares to 450M.
- Conversion conditions include approval at 2024 annual meeting, board adoption, and Delaware filing of new charter.
- Preferred stockholders vote on as-converted basis on all matters; no separate class vote.
- Issuance is part of previously announced private placement; par value $0.01 per share.
- Authorized common shares to increase from 300M to 450M under proposed Sixth Amended and Restated Charter.

## SEC filing metadata
- accession: 0001193125-24-065928
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2024-03-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000119312524065928/0001193125-24-065928-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000119312524065928/d783185d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-065928
- JSON: https://secwatch.observer/filing/0001193125-24-065928.json
- Plain text: https://secwatch.observer/filing/0001193125-24-065928.txt

## Key facts
- Governance Changes
  LEXICON PHARMACEUTICALS, INC.: Filing of Certificate of Designations for Series A Convertible Preferred Stock and planned increase in authorized common shares from 300,000,000 to 450,000,000 upon stockholder approval and adoption of New Charter (effective 2024-03-12).
  - Change: charter amendment
  - Effective: 2024-03-12
  source text: On March 12, 2024, in connection with the previously announced private placement by Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), of preferred stock to be designated as Series A Convertible Preferred Stock, par value $0.01 per share (the “ Preferred Stock ”), the Company filed with the Secretary of State of the State of Delaware to be effective upon filing the Certificate of Designations of Series A Convertible Preferred Stock of the Company (the “ Certificate of Designations ”), in the form approved and adopted by the board of directors of the Company, which sets forth the terms of the Preferred Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1062822/000119312524065928/0001193125-24-065928-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.